Physician profile
Daniel Tan
NPI 1578971248
$2,654.03
in general payments reported to CMS, 2019-2025
17 companies · $698 in 2025
The $698 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $311 · 2024: $1,646 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,654.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $420.76 | 2024 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $408.69 | 2023-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $285.89 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $247.86 | 2024 | Nuedexta, Abilify Maintena, Abilify Asimtufii |
| Gynesonics, INC. | $148.25 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Janssen Pharmaceuticals, INC | $147.66 | 2024 | Invega Sustenna |
| Braeburn INC. | $125.00 | 2025 | Brixadi |
| Acadia Pharmaceuticals INC | $125.00 | 2024 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $100.18 | 2023-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $100.08 | 2024 | Qelbree |
| Biogen, INC. | $100.00 | 2024 | Zurzuvae |
| Pfizer INC. | $89.96 | 2024 | |
| Lundbeck LLC | $73.78 | 2024 | Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $59.72 | 2024 | Uzedy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $54.52 | 2024 | Auvelity |
| Indivior INC. | $41.68 | 2024 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.